Evidence map›Paper›PMID 38248655›Full record

ArticleMarine drugs2023

Prospective Antiviral Effect of

Reem Binsuwaidan, Thanaa A El-Masry, Mostafa El-Sheekh, Mohamed G Seadawy, Mofida E M Makhlof, Shaimaa M Aboukhatwa, Nagla A El-Shitany, Kadreya E Elmorshedy, Maysa M F El-Nagar, Maisra M El-Bouseary

Open access · goldAbstract read
In one paragraph

Article in Marine drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Neuritogenic effects of Ulva lactuca aqueous extract on Neuro-2a cells.BMC complementary medicine and therapies · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Reem BinsuwaidanDepartment of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.ORCID 0000-0003-1406-282X
Thanaa A El-MasryDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt.
Mostafa El-SheekhBotany Department, Faculty of Science, Tanta University, Tanta 31527, Egypt.ORCID 0000-0002-2298-6312
Mohamed G SeadawyBiological Prevention Department, Egypt Army, Cairo 31527, Egypt.ORCID 0000-0001-6102-723X
Mofida E M MakhlofBotany and Microbiology Department, Faculty of Science, Damanhour University, Damanhour 22511, Egypt.
Shaimaa M AboukhatwaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt.ORCID 0000-0002-5013-7158
Nagla A El-ShitanyDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt.
Kadreya E ElmorshedyDepartment of Anatomy, Faculty of Medicine, Tanta University, Tanta 31527, Egypt.
Maysa M F El-NagarDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt.ORCID 0000-0001-5807-1117
Maisra M El-BousearyDepartment of Microbiology and Immunology, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt.ORCID 0000-0001-6503-0719
Tanta University · EGCairo University · EGDamanhour University · EGPrincess Nourah bint Abdulrahman University · SA

Funding

Reem Binsuwaidan PNURSP2023R304
6 · The paper itself

Abstract

Marine algal extracts exhibit a potent inhibitory effect against several enveloped and non-enveloped viruses. The infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has several adverse effects, including an increased mortality rate. The anti-COVID-19 agents are still limited; this issue requires exploring novel, effective anti-SARS-CoV-2 therapeutic approaches. This study investigated the antiviral activity of an aqueous extract of

Indexed as

Biological ProductsCOVID-19Edible SeaweedsUlvaAntiviral AgentsSARS-CoV-2Antiviral AgentsBiological Productsanti-SARS-CoV-2antiviralEgyptUlva lactucaulvan

Identifiers

PMID38248655
PMCPMC10817659
OpenAlexW4390467772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.